多种疗法对实验性外伤性视神经病变小鼠模型的干预。

IF 1.2 4区 医学 Q3 OPHTHALMOLOGY
David T Tse, Hua Wang, Wensi Tao, Robert C O'Brien, Brian C Tse, Daniel Pelaez
{"title":"多种疗法对实验性外伤性视神经病变小鼠模型的干预。","authors":"David T Tse, Hua Wang, Wensi Tao, Robert C O'Brien, Brian C Tse, Daniel Pelaez","doi":"10.1097/IOP.0000000000002917","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To test a novel early polytherapy treatment strategy targeting mitochondrial bioenergetics, glutamate excitotoxicity, and sterile inflammatory response molecular pathways associated with retinal ganglion cell survival following optic nerve trauma.</p><p><strong>Methods: </strong>Twenty C57BL/6J mice were subjected to sonication-induced traumatic optic neuropathy injury. The control group (n = 10) received intravitreal, retrobulbar, and subcutaneous phosphate buffered saline injections on days 0 and 3 (no repeat retrobulbar vehicle). On day 0, the treatment group (n = 10) received injections of intravitreal interleukin-1 receptor antagonist with ketamine, retrobulbar ropivacaine, and subcutaneous etanercept. Treatment group animals had 1% (wt/vol) N-acetylcysteine ad libitum supplemented in drinking water from day 1. On day 3, intravitreal pan-ephrin receptor antagonist peptide and subcutaneous elamipretide and etanercept injections were given. Pattern electroretinogram assessments continued at weeks 0, 1, 2, 4, 6, 8, 10, and 12. Optical coherence tomography retinal layer thickness was measured on naive, control, and treatment groups at week 12. The whole mount retinas were harvested for retinal ganglion cell quantitation.</p><p><strong>Results: </strong>At 12 weeks, the averaged retinal ganglion cell density count in the control group was lower (413.37 ± 41.77 cells/mm2) compared with treatment (553.97 ± 18.00 cells/mm2; p < 0.001) and naive (595.94 ± 30.67cells/mm2; p < 0.001) groups. Ganglion cell complex layer thicknesses showed control group (49.29 ± 5.48 μm) thinner than the treated (61.00 ± 2.57 μm; p = 0.004) and naive (67.00 ± 6.12 μm; p = 0.004) groups. No significant difference was seen at 12 weeks between the treated and naive groups. Pattern electroretinogram recordings in the control group revealed a statistically significant decrease in amplitudes for all time points. Apart from week 8, the amplitudes in the treatment group did not significantly differ from the baseline at any time point.</p><p><strong>Conclusions: </strong>Early combinatorial therapeutic intervention to address disparate molecular pathways following optic nerve trauma effectively halts retinal neurons' progressive structural and functional degeneration.</p>","PeriodicalId":19588,"journal":{"name":"Ophthalmic Plastic and Reconstructive Surgery","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Polytherapy Intervention in an Experimental Traumatic Optic Neuropathy Mouse Model.\",\"authors\":\"David T Tse, Hua Wang, Wensi Tao, Robert C O'Brien, Brian C Tse, Daniel Pelaez\",\"doi\":\"10.1097/IOP.0000000000002917\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To test a novel early polytherapy treatment strategy targeting mitochondrial bioenergetics, glutamate excitotoxicity, and sterile inflammatory response molecular pathways associated with retinal ganglion cell survival following optic nerve trauma.</p><p><strong>Methods: </strong>Twenty C57BL/6J mice were subjected to sonication-induced traumatic optic neuropathy injury. The control group (n = 10) received intravitreal, retrobulbar, and subcutaneous phosphate buffered saline injections on days 0 and 3 (no repeat retrobulbar vehicle). On day 0, the treatment group (n = 10) received injections of intravitreal interleukin-1 receptor antagonist with ketamine, retrobulbar ropivacaine, and subcutaneous etanercept. Treatment group animals had 1% (wt/vol) N-acetylcysteine ad libitum supplemented in drinking water from day 1. On day 3, intravitreal pan-ephrin receptor antagonist peptide and subcutaneous elamipretide and etanercept injections were given. Pattern electroretinogram assessments continued at weeks 0, 1, 2, 4, 6, 8, 10, and 12. Optical coherence tomography retinal layer thickness was measured on naive, control, and treatment groups at week 12. The whole mount retinas were harvested for retinal ganglion cell quantitation.</p><p><strong>Results: </strong>At 12 weeks, the averaged retinal ganglion cell density count in the control group was lower (413.37 ± 41.77 cells/mm2) compared with treatment (553.97 ± 18.00 cells/mm2; p < 0.001) and naive (595.94 ± 30.67cells/mm2; p < 0.001) groups. Ganglion cell complex layer thicknesses showed control group (49.29 ± 5.48 μm) thinner than the treated (61.00 ± 2.57 μm; p = 0.004) and naive (67.00 ± 6.12 μm; p = 0.004) groups. No significant difference was seen at 12 weeks between the treated and naive groups. Pattern electroretinogram recordings in the control group revealed a statistically significant decrease in amplitudes for all time points. Apart from week 8, the amplitudes in the treatment group did not significantly differ from the baseline at any time point.</p><p><strong>Conclusions: </strong>Early combinatorial therapeutic intervention to address disparate molecular pathways following optic nerve trauma effectively halts retinal neurons' progressive structural and functional degeneration.</p>\",\"PeriodicalId\":19588,\"journal\":{\"name\":\"Ophthalmic Plastic and Reconstructive Surgery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-02-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmic Plastic and Reconstructive Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/IOP.0000000000002917\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic Plastic and Reconstructive Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IOP.0000000000002917","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:测试一种针对视神经损伤后视网膜神经节细胞存活相关的线粒体生物能量学、谷氨酸兴奋毒性和无菌炎症反应分子途径的新型早期多疗法治疗策略。方法:将20只C57BL/6J小鼠超声致外伤性视神经损伤。对照组(n = 10)于第0天和第3天接受玻璃体内、球后和皮下磷酸盐缓冲盐水注射(无重复球后载药)。第0天,治疗组(n = 10)给予玻璃体内注射含氯胺酮、球后罗哌卡因、依那西普皮下注射白介素-1受体拮抗剂。处理组动物从第1天开始在饮用水中随意添加1% (wt/vol) n -乙酰半胱氨酸。第3天给予玻璃体内注射泛肾上腺素受体拮抗剂肽,皮下注射依那西普和依拉米普肽。视网膜电图模式评估在第0、1、2、4、6、8、10和12周继续进行。光学相干断层扫描视网膜层厚度测量在第12周的初始组,对照组和治疗组。取全组视网膜进行视网膜神经节细胞定量。结果:12周时,对照组视网膜神经节细胞平均密度计数(413.37±41.77细胞/mm2)低于治疗组(553.97±18.00细胞/mm2);P < 0.001)和naive(595.94±30.67cells/mm2;P < 0.001)组。神经节细胞复合体层厚度:对照组(49.29±5.48 μm)比处理组(61.00±2.57 μm)薄;P = 0.004)和幼稚(67.00±6.12 μm;P = 0.004)组。12周时,治疗组和未治疗组之间无显著差异。对照组的视网膜电图记录显示,在所有时间点上,振幅都有统计学意义上的显著下降。除第8周外,治疗组的波幅在任何时间点与基线均无显著差异。结论:针对视神经损伤后不同分子通路的早期联合治疗干预可有效阻止视网膜神经元的进行性结构和功能退化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Polytherapy Intervention in an Experimental Traumatic Optic Neuropathy Mouse Model.

Purpose: To test a novel early polytherapy treatment strategy targeting mitochondrial bioenergetics, glutamate excitotoxicity, and sterile inflammatory response molecular pathways associated with retinal ganglion cell survival following optic nerve trauma.

Methods: Twenty C57BL/6J mice were subjected to sonication-induced traumatic optic neuropathy injury. The control group (n = 10) received intravitreal, retrobulbar, and subcutaneous phosphate buffered saline injections on days 0 and 3 (no repeat retrobulbar vehicle). On day 0, the treatment group (n = 10) received injections of intravitreal interleukin-1 receptor antagonist with ketamine, retrobulbar ropivacaine, and subcutaneous etanercept. Treatment group animals had 1% (wt/vol) N-acetylcysteine ad libitum supplemented in drinking water from day 1. On day 3, intravitreal pan-ephrin receptor antagonist peptide and subcutaneous elamipretide and etanercept injections were given. Pattern electroretinogram assessments continued at weeks 0, 1, 2, 4, 6, 8, 10, and 12. Optical coherence tomography retinal layer thickness was measured on naive, control, and treatment groups at week 12. The whole mount retinas were harvested for retinal ganglion cell quantitation.

Results: At 12 weeks, the averaged retinal ganglion cell density count in the control group was lower (413.37 ± 41.77 cells/mm2) compared with treatment (553.97 ± 18.00 cells/mm2; p < 0.001) and naive (595.94 ± 30.67cells/mm2; p < 0.001) groups. Ganglion cell complex layer thicknesses showed control group (49.29 ± 5.48 μm) thinner than the treated (61.00 ± 2.57 μm; p = 0.004) and naive (67.00 ± 6.12 μm; p = 0.004) groups. No significant difference was seen at 12 weeks between the treated and naive groups. Pattern electroretinogram recordings in the control group revealed a statistically significant decrease in amplitudes for all time points. Apart from week 8, the amplitudes in the treatment group did not significantly differ from the baseline at any time point.

Conclusions: Early combinatorial therapeutic intervention to address disparate molecular pathways following optic nerve trauma effectively halts retinal neurons' progressive structural and functional degeneration.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.50
自引率
10.00%
发文量
322
审稿时长
3-8 weeks
期刊介绍: Ophthalmic Plastic and Reconstructive Surgery features original articles and reviews on topics such as ptosis, eyelid reconstruction, orbital diagnosis and surgery, lacrimal problems, and eyelid malposition. Update reports on diagnostic techniques, surgical equipment and instrumentation, and medical therapies are included, as well as detailed analyses of recent research findings and their clinical applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信